Inflammation of any part, segment or lobe, of the lung parenchyma.
| Excerpt | Reference |
|---|
| "Radiation pneumonitis is a well-recognized complication of therapeutic thoracic irradiation that is occasionally fatal." | ( Miura, G, 1992) |
| "Amiodarone pneumonitis is a serious complication that may lead to fatal lung fibrosis." | ( Camargo, EE; Cukier, A; Meneguetti, JC; Soares Júnior, J; Teixeira, LR; Terra-Filho, M; Vargas, FS, 1990) |
| "Radiation pneumonitis is a life-threatening result of therapeutic thoracic irradiation, yet its mechanisms are poorly understood." | ( Brigham, KL; Holm, BA; Loyd, JE; Malcolm, AW; Tillman, BF, 1989) |
| "Radiation pneumonitis are well recognized as complications of radiotherapy for the thoracic malignancies." | ( Hashimura, T; Imajo, Y; Kono, M, 1989) |
| "Methotrexate pneumonitis is emerging as one of the most unpredictable and potentially serious adverse effects associated with the use of low dose, pulse methotrexate in treating rheumatoid arthritis (RA)." | ( McKendry, RJ; Searles, G, 1987) |
| "Pneumonitis is a serious side effect of MTX therapy (P-MTX)." | ( Atchison, MH; Carroll, GJ; Cook, NJ; D'Souza, I; Leslie, AL; Phatouros, CC; Thomas, R, 1994) |
| "Methotrexate pneumonitis is one of the most unpredictable and potentially serious adverse effects associated with the use of low-dose pulse methotrexate in treating rheumatoid arthritis." | ( Chen, CH; Shin, JF; Tsai, JJ; Wang, SR, 1993) |
| "Pneumonitis is an infrequent complication of methotrexate therapy." | ( Fanning, J; Horrigan, TJ; Marcotte, MP, 1997) |
| "Pneumonitis is a well recognized side effect of this drug, but occurs at low doses in the treatment of NHL." | ( Bloor, AJ; Marcus, RE; Seale, JR, 1998) |
| "Pneumonitis is a serious and unpredictable side-effect of treatment with methotrexate (MTX) that may become life-threatening." | ( Colby, TV; Helmers, RA; Imokawa, S; Leslie, KO, 2000) |
| "Since lung inflammation is known to occur and persist only at sufficient particle dose, this secondary pathway is considered to contain a threshold (Greim et al." | ( Schins, RP, 2002) |
| "Pneumonitis is a rare and potentially deadly complication of gemcitabine." | ( Ash-Bernal, R; Browner, I; Erlich, R, 2002) |
| "Methotrexate pneumonitis is an unpredictable and life-threatening side effect of methotrexate therapy." | ( Hsieh, TY; Hsu, PC; Huang, WN; Jan, YJ; Lan, JL, 2003) |
| "Interstitial pneumonitis is a rare disease that is seen in the context of some infections (e." | ( Denton, M; Goldsmith, DJ; Haydar, AA; Rees, J; West, A, 2004) |
| "The onset of the lung inflammation is delayed until 49 weeks post-exposure." | ( Lee, SH; Richards, RJ, 2004) |
| "Lung inflammation is a key response to increased levels of particulate air pollution (PM); however, the cellular mechanisms leading to this response are poorly understood." | ( Godleski, JJ; González-Flecha, B; Lawrence, J; Rhoden, CR, 2004) |
| "Since MTX pneumonitis is a potentially fatal complication, new pulmonary symptoms, even in patients on low-dose MTX treatment, should be appropriately investigated." | ( Froudarakis, M; Katsogridakis, K; Koutsopoulos, A; Kritikos, H; Mazokopakis, E; Voloudaki, A; Vrentzos, G, 2004) |
| "Interstitial pneumonitis is an ill-defined side effect of sirolimus, a new immunosuppressant drug recently introduced for patients having organ transplantation." | ( Champion, L; Israël-Biet, D; Kreis, H; Mamzer-Bruneel, MF; Morelon, E; Peraldi, MN; Porcher, R; Stern, M, 2006) |
| "Amiodarone pneumonitis is a relevant differential diagnosis for heart failure (HF) patients using amiodarone that are admitted to the emergency ward with dyspnea." | ( Bacal, F; Bocchi, EA; Demarchi, LM; Drager, LF; Fajardo, GM; Pires, PV; Silva, CP; Souza, GE, 2006) |
| "Amiodarone-related pneumonitis is a potentially limiting factor for amiodarone usage." | ( Chang, SN; Chiang, FT; Hsu, KL; Hwang, JJ; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD, 2007) |
| "Pneumonitis is a serious and unpredictable side-effect of treatment with methotrexate (MTX) that may result in a life-threatening outcome." | ( Ding, Z; Qian, J; Wang, Y; Xie, X; Zhang, D, 2008) |
| "Lung inflammation is a pivotal phenomenon in the pathogenesis of cystic fibrosis." | ( Abely, M; Chiron, R; Fayon, M, 2008) |
| "Drug-induced pneumonitis is a serious and an unpredictable side effect of chemotherapy in patients with malignant lymphoma." | ( Daimaru, O; Fukaya, N; Imai, T; Ito, S; Nagata, T; Uchida, H; Yamane, T; Yoshiya, K, 2008) |
| "Mucositis and pneumonitis are the most commonly reported toxicities, but they rarely lead to treatment discontinuation." | ( Giles, F; Kelly, K; Mahalingam, D; Mita, A; Mita, M; Sankhala, K, 2009) |
| "Pneumonitis is a rare but serious complication of docetaxel treatment." | ( Kuip, E; Muller, E, 2009) |
| "Chronic pulmonary inflammation is associated with increased lung cancer risk, but the underlying process remains unknown." | ( Chiu, RK; Godschalk, RW; Güngör, N; Haegens, A; Knaapen, AM; van Schooten, FJ; Wouters, EF, 2010) |
| "Noninfectious pneumonitis is a known class effect of mammalian target of rapamycin (mTOR) inhibitors." | ( Akaza, H; Calvo, E; Camus, P; Endo, M; Escudier, B; Kay, A; Kpamegan, E; Motzer, RJ; Ravaud, A; Robson, M; Uemura, H; White, DA, 2010) |
| "Pulmonary inflammation is a major contributor to morbidity in a variety of respiratory disorders, but treatment options are limited." | ( Dorr, AD; Goddard, ME; O'Dea, KP; Takata, M; Wilson, MR; Yamamoto, H, 2010) |
| "Lung inflammation is a key feature of ALI." | ( de Prost, N; Melo, MF; Tucci, MR, 2010) |
| "mTORi associated pneumonitis is not a rare disease." | ( Errasti, M; Errasti, P; Izquierdo, D; Lavilla, FJ; Martín, P; Romero, A; Slon, F, 2010) |
| "Allergic lung inflammation is impaired in diabetic rats and is restored by insulin treatment." | ( Anger, DB; Jancar, S; Martins, DO; Martins, JO; Sannomiya, P; Wittlin, BM, 2010) |
| "Pneumonitis is a well-known complication following aspiration of ingested liquid hydrocarbons." | ( Rhyee, SH; Weibrecht, KW, 2011) |
| "Neutrophil-dominant pulmonary inflammation is an important feature of chronic obstructive pulmonary disease (COPD)." | ( Iwata, M; Kobayashi, M; Kubo, S; Miyata, K; Shimizu, Y; Takahashi, K, 2012) |
| "Pneumonitis is a complication of high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) regimens containing BCNU." | ( Abramson, JS; Armand, P; Brown, JR; Chen, YB; Feng, Y; Fisher, DC; Freedman, AS; Jacobsen, ED; LaCasce, AS; Lane, AA; McAfee, SL; Neuberg, DS; Spitzer, TR, 2012) |
| "Acute drug-induced pneumonitis is a rare but serious complication of rituximab." | ( Arulkumaran, N; Cecconi, M; Chua, F; Kiely, P; Suleman, R, 2012) |
| "Allergic pulmonary inflammation is not up-regulated by inhalation of the pollutants ethanol and nano-TiO(2)." | ( Charbonneau, M; Cloutier, Y; Noël, A; Renzi, PM; Scarino, A; Tardif, R; Truchon, G; Vincent, R, 2012) |
| "Hydroxyurea-induced pneumonitis is unusual." | ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014) |
| "Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutrophils (PMNs) into the different compartments of the lung, passing an endothelial and epithelial barrier." | ( Bury, A; Konrad, FM; Ngamsri, KC; Reutershan, J; Schick, MA, 2015) |
| "SR-associated pneumonitis is a rare but potentially serious complication due to its increasing utilization in transplant patients." | ( Buenasmañanas, D; García, E; Martín, C; Rojas, R, 2015) |
| "SR associated pneumonitis is a potentially fatal side effect." | ( Buenasmañanas, D; García, E; Martín, C; Rojas, R, 2015) |
| "MTX-induced pneumonitis is a rare, although potentially severe complication of this treatment." | ( Fiehn, C, 2015) |
| "Lung inflammation is a major adverse effect of therapy with the antitumor drug bleomycin (BLM)." | ( Ishii, M; Kage, Y; Mori, Y; Nakano, Y; Negoro, T; Numata, T; Ohbayashi, M; Shimizu, S; Takenaka, M; Toda, T; Yamamoto, S; Yamamoto, T; Yonezawa, R, 2016) |
| "Ozone-induced lung inflammation is mediated, in part, by the innate immune system." | ( Bushel, PR; Ciencewicki, JM; Gerrish, K; Kleeberger, SR; Li, J; McCaw, ZR; Verhein, KC, 2016) |
| "Also, TNF-α-induced lung inflammation is not sufficient to drive murine arthritis." | ( Bawadekar, M; Gendron-Fitzpatrick, A; Lundblad, LK; Nicholas, AP; Rebernick, R; Shelef, MA; Shim, D; Thompson, PR; Warner, TF, 2016) |
| "Hypersensitivity pneumonitis is a syndrome associated with lung inflammation from the inhalation of airborne antigens, such as molds and dust." | ( Escobedo Calderon, SP; Heston, S; Woloski, JR, 2016) |
| "As interstitial pneumonitis is a rare adverse event during anagrelide-therapy administration, physicians must be vigilant in identifying drug-induced interstitial pneumonitis in patients treated with anagrelide because early detection can decrease the severity and prevent mortality." | ( Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M, 2017) |
| "Everolimus-induced pneumonitis is associated with improved outcome in patients with mRCC and may serve as a biomarker of everolimus efficacy." | ( Bono, P; Donskov, F; Laukka, M; Peltola, K; Penttilä, P; Rautiola, J, 2017) |
| "Noninfective pneumonitis is a class-related effect within mammalian target of rapamycin (mTOR) inhibitors, including everolimus, and can occasionally be severe." | ( Almeida, F; Amorim, S; Santos, L; Sarmento, A, 2018) |
| "Pneumonitis is considered to be a rare manifestation although congenital CMV infection presents with various non-specific findings." | ( Goishi, K; Hosokawa, S; Ito, Y; Kashiwa, N; Lee-Yoshimoto, M; Mori, T; Ono, H; Shichino, H; Torii, Y, 2018) |
| "Radiation pneumonitis is a major dose-limiting complication in thoracic radiation therapy (RT) and presents clinically in the first few months after RT." | ( Alavi, A; Goodman, CR; Houshmand, S; Kalbasi, A; Rice, SR; Saboury, B; Salavati, A; Simone, CB; Vujaskovic, Z; Werner, TJ, 2019) |
| "PET-pneumonitis is common in early post-CRT/RT, but pattern recognition may assist in response assessment by FDG-PET/CT." | ( Akhurst, T; Ball, DL; Bressel, M; Callahan, JW; Everitt, SJ; Hicks, RJ; Hofman, MS; Iravani, A; Mac Manus, MP; Siva, S; Turgeon, GA, 2019) |
| "Interstitial pneumonitis is a rare drug adverse effect." | ( Arnault, JP; Auquier, M; Chaby, G; Lafabregue, E; Lok, C; Magois, E, 2019) |
| "Pneumonitis is the leading cause of death associated with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) against non-small cell lung cancer (NSCLC)." | ( Ando, K; Arata, S; Homma, M; Homma, T; Kishino, Y; Kusumoto, S; Manabe, R; Ohba, M; Ohmori, T; Sagara, H; Takimoto, M; Tsurutani, J; Yamaoka, T, 2019) |
| "Drug-induced pneumonitis is rare, and can result in death." | ( Ahn, JH, 2020) |
| "Pneumonitis is a major complication among adults with measles." | ( Dourakis, SP; Fragkou, PC; Karofylakis, E; Kavvatha, D; Liatsos, GD; Marantos, T; Pirounaki, M; Sambatakou, H; Sympardi, S; Thomas, K; Tsiodras, S, 2020) |
| "Lung inflammation is associated with many respiratory conditions." | ( Baer, B; McCaig, L; Veldhuizen, R; Yamashita, C, 2020) |
| "Many causes of lung inflammation are associated with a lung metabolic profile characterized by increased oxidative stress, a shift toward the use of other forms of energy production, and/or a depleted energy state." | ( Altmann, C; Ambruso, SL; Bagchi, RA; Baker, PR; Faubel, S; Fox, B; Gil, HW; Park, B; Reisz, JA, 2021) |
| "Imaging of acute lung inflammation is pivotal to evaluate innovative ventilation strategies." | ( Benzerdjeb, N; Bitker, L; Costes, N; Dhelft, F; Lancelot, S; Le Bars, D; Orkisz, M; Richard, JC, 2022) |
| "Drug-related ILD/pneumonitis is a diagnosis of exclusion; other possible causes of lung injury/imaging findings must be ruled out for an accurate diagnosis." | ( Andre, F; Bartholmai, BJ; Conte, P; Kato, T; Lancaster, LH; Li, BT; Naidoo, J; Nicholson, AG; Nishino, M; Powell, CA; Schumacher-Wulf, E; Shitara, K; Swain, SM; Tsurutani, J, 2022) |
| "Pneumonitis is a critical driving factor of COPD and exposure to air pollutants (e." | ( Cha, H; Chen, Y; Cho, AE; Crowley, L; Eun Moon, J; Han Chang, M; Hee Jo, E; Hee Lee, S; Hoon Pan, J; Hyun Park, J; Hyup Lee, J; Jin Lim, Y; Kim, HW; Kyeom Kim, J; Le, B; Li, Y; Nukhet, AB; Pil Pack, S; Rae Cho, Y; Zhao, J; Zhong, Y, 2023) |
| "Immune-related pneumonitis is an uncommon but potentially life-threatening adverse event associated with anti-programmed cell death protein-1 therapy, and has a higher recurrence rate than that of other pneumonitis." | ( Gao, Q; Li, T; Ma, B; Zhao, L; Zhou, Y, 2023) |
| "Pulmonary inflammation is one of the most reported tissue inflammations in clinic." | ( Bian, Q; Chen, S; Gao, J; Huang, T; Lin, R; Su, Y; Sun, H; Wu, H; Xu, D; Zhang, J; Zhang, T; Zheng, X, 2023) |
| Excerpt | Reference |
|---|
| "A sever Pneumocystis carinii pneumonitis developed, but was successfully treated with pentamidine, sulfametoxazole with trimetoprim and transfer factor." | ( Hertz, H; Lundsteen, C; Pedersen, FK; Platz, P; Thomsen, M, 1977) |
| "Radiation pneumonitis usually occurs within 1-3 months after the completion of radiation therapy." | ( Fujii, T; Hamamoto, K; Higashino, H; Iio, A; Itoh, H; Kataoka, M; Kawamura, M; Mogami, H; Nishiyama, Y, 1992) |
| "We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy." | ( Mashiach, R; Ovadia, J; Schoenfeld, A; Vardy, M, 1992) |
| "In five patients, after resolution of pneumonitis and after an almost normal BAL cell profile was obtained, resumption of treatment with the suspected drug for two to four weeks induced a rise in lymphocyte population in a third BAL." | ( Akoun, GM; Cadranel, JL; D'Ortho, MP; Mayaud, CM; Milleron, BJ, 1991) |
| "Estradiol (E) abolished clearing of pulmonary inflammation in 2-month-old male MRL/MpJ-lpr/lpr (MRL/l) mice treated with cyclophosphamide (CY)." | ( Braun, SR; McKenzie, WN; O'Sullivan, FX; Palomo, T; Seggev, JS; Sunderrajan, EV; Walker, SE, 1991) |
| "Radiation pneumonitis was seen in 3% of patients receiving radiation therapy alone." | ( Mauch, P; Tarbell, NJ; Thompson, L, 1990) |
| "Radiation pneumonitis are well recognized as complications of radiotherapy for the thoracic malignancies." | ( Hashimura, T; Imajo, Y; Kono, M, 1989) |
| "Radiological pneumonitis was observed in 57% (12/21) of patients receiving combined modality treatment compared to 71% (15/21) of patients receiving radiation alone with evidence of a radiation dose-response relationship for the appearance of pneumonitis in both groups of patients (p greater than 0." | ( Ashley, SE; Cherryman, G; Glaholm, J; Magrini, S; Repetto, L; Smith, IE; Yarnold, JR, 1988) |
| "This report describes a fatal pneumonitis occurring in a breast cancer patient while on adjuvant treatment with radiotherapy and medroxyprogesterone acetate." | ( De Greve, J; Deleu, D; Storme, G; Warson, F, 1985) |
| "Methotrexate pneumonitis is emerging as one of the most unpredictable and potentially serious adverse effects associated with the use of low dose, pulse methotrexate in treating rheumatoid arthritis (RA)." | ( McKendry, RJ; Searles, G, 1987) |
| "Localized pneumonitis and fibrosis are well-known sequelae of this treatment." | ( Jochelson, MS; Tarbell, NJ; Weinstein, HJ, 1986) |
| "A case of pneumonitis and pulmonary fibrosis occurring during long term treatment with amiodarone hydrochloride is described." | ( Cosentino, G; De Vuono, T; Pesola, A; Vercillo, C, 1985) |
| "Chemotherapy pneumonitis, confirmed by lung biopsy, responded dramatically to prednisone with negligible sequelae." | ( Goedert, JJ; Smith, FP; Tsou, E; Weiss, RB, 1983) |
| "To examine the effect of lung inflammation on lung volumes and carbon monoxide transfer and their relationship to the ventilatory and gas exchange responses to exercise, a prospective study was performed in patients having Hodgkin's disease, with no evidence of intrathoracic involvement, who received prophylactic mantle-field radiotherapy to the chest." | ( Al-Hillawi, A; Jelliffe, AM; Johnson, NM; Jones, PW; Wakefield, JM, 1984) |
| "Chemotherapy-related pneumonitis developed in eight patients during treatment for breast cancer." | ( Godwin, TA; Orenstein, M; Stover, DE; White, DA, 1984) |
| "One drug recipient developed mild pneumonitis during the study which resolved with therapy, whereas eight placebo recipients developed varicella-related complications which led to death in two patients (P less than 0." | ( Alford, CA; Bryson, Y; Connor, JD; Haynes, R; Hilty, M; Soong, SJ; Whitley, R, 1982) |
| "A patient who developed pneumonitis immediately after the administration of carmustine (BCNU), within exactly the same field as previous irradiation, is presented." | ( Agrawal, S; Geddes, DM; Gore, M; Thomas, PS, 1995) |
| "As methotrexate pneumonitis was suspected the drug was discontinued and prednisolone administered (50 mg daily for 3 days, gradually reducing over 7 days)." | ( Adamek, RJ; Bitsch, T; Israel, CW; Ricken, D; Weber, K; Wegener, M, 1995) |
| "For the treatment of CMV-associated pneumonitis, it is recommended that ganciclovir and IVIG be used in combination for the bone marrow transplant recipient and that ganciclovir be used with or without IVIG in patients in other transplantation groups." | ( Zaia, JA, 1993) |
| "Methotrexate pneumonitis is one of the most unpredictable and potentially serious adverse effects associated with the use of low-dose pulse methotrexate in treating rheumatoid arthritis." | ( Chen, CH; Shin, JF; Tsai, JJ; Wang, SR, 1993) |
| "In a model of pulmonary inflammation and fibrosis induced by the antineoplastic antibiotic, bleomycin, we have demonstrated that explanted alveolar macrophages secrete progressively increasing quantities of a biologically active form of TGF-beta 1, the secretion of which was maximal 7 days after bleomycin administration." | ( Corne, S; Khalil, N; Whitman, C; Yacyshyn, H, 1996) |
| "We describe a case of pneumonitis in a patient receiving selective intra-arterial chemotherapy for locally advanced breast cancer." | ( Doughty, JC; Kane, E; McArdle, CS; McCarter, DH; McLean, AD; Reid, AW, 1996) |
| "We report four cases of acute pneumonitis due either to interferon, or a herbal drug, "Sho-saiko-to", or both in combination, in patients with chronic active hepatitis, focusing on its pathogenesis and response to prednisolone therapy." | ( Abe, Y; Ameshima, S; Ishizaki, T; Ito, S; Kitagawa, M; Kuriyama, M; Nakai, T; Sasaki, F; Shiozaki, K; Takahashi, H, 1996) |
| "Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy." | ( Akerley, W; Choy, H; Chung, C; Graziano, S; Safran, H, 1996) |
| "Described is a case of pneumonitis after treatment of an ectopic pregnancy." | ( Fanning, J; Horrigan, TJ; Marcotte, MP, 1997) |
| "The role of corticosterone in pulmonary inflammation in this model was investigated further by treating MMQ tumor-bearing rats with dexamethasone." | ( Adler, RA; Bowers, A; Gunnison, AF; Nadziejko, C, 1997) |
| "Acute bilateral pneumonitis occurs in less than 1% of individuals receiving 3-hour infusions of paclitaxel, and responds dramatically to parenteral corticosteroid therapy." | ( Bilgrami, S; Khan, A; McNally, D; Tutschka, PJ, 1997) |
| "Arthritis, pneumonitis, and mortality were analyzed in me/me mice treated with a novel, soluble, dimeric TNF receptor I (sTNFRI) molecule capable of high-affinity binding and neutralization of TNFalpha." | ( Edwards, CK; Mountz, JD; Su, X; Yang, P; Zhou, T, 1998) |
| "The extent of pulmonary inflammation that occurred as a result of intratracheal injection of glucan was not affected by transfer of cultured cells from glucan-treated animals." | ( Cherne, A; Gott, K; Schuyler, M, 1998) |
| "We present two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin's lymphoma." | ( Bloor, AJ; Marcus, RE; Seale, JR, 1998) |
| "The incidence of radiation pneumonitis was compared with that among patients in our database whose treatments did not include paclitaxel (n = 1286)." | ( Assaad, SI; Kuter, I; Niemierko, A; Powell, SN; Roche, M; Schoenthaler, R; Taghian, AG; Younger, J, 2001) |
| "We suspected drug-induced pneumonitis because of her history of drug administration for upper respiratory infection." | ( Higa, F; Ishimine, T; Kawakami, K; Miyara, T; Miyazato, A; Nakamoto, A; Nakamura, H; Saito, A; Tamaki, Y; Tateyama, M; Tohyama, M; Toyama, M, 2002) |
| "Drug induced pneumonitis was suspected so the antituberculous regimen was discontinued and methylprednisolone was administered." | ( Harada, M; Kotani, K; Kunichika, N; Miyahara, N; Takeyama, H; Tanimoto, M, 2002) |
| "Survivors with aspiration pneumonitis (13/75 (17%)) or with an aspiration event (20/60 (33%)) were significantly more likely not to be treated with an antibiotic or to be treated for 1 day or less than those with pneumonia (0/41; P <." | ( Goodnough, S; Mylotte, JM; Naughton, BJ, 2003) |
| "She presented with left pneumonitis and improved with antibiotic therapy." | ( Aggarwal, AN; Gupta, D; Jindal, SK, 2002) |
| "Methotrexate pneumonitis is an unpredictable and life-threatening side effect of methotrexate therapy." | ( Hsieh, TY; Hsu, PC; Huang, WN; Jan, YJ; Lan, JL, 2003) |
| "Since MTX pneumonitis is a potentially fatal complication, new pulmonary symptoms, even in patients on low-dose MTX treatment, should be appropriately investigated." | ( Froudarakis, M; Katsogridakis, K; Koutsopoulos, A; Kritikos, H; Mazokopakis, E; Voloudaki, A; Vrentzos, G, 2004) |
| "Using a rat model of acute lung inflammation caused by intratracheally administered LPS (10 microg Pseudomonas aeruginosa LPS), the authors examined the effect of aerosol-administered vitamin E, in this case alpha-tocopherol, on several indices of lung inflammation which are increased by LPS treatment." | ( Allard, JD; Cho, OJ; Chung, JH; Fini, MA; Hansen, BN; Hybertson, BM; Lee, YM; Repine, JE; Shibao, GN, 2005) |
| "We report a case of bleomycin-induced pneumonitis in a patient treated for Hodgkin lymphoma with severe clinical respiratory symptoms, a marked restrictive pattern on pulmonary function tests, and FDG avid lymphadenopathy and diffuse increased uptake involving both lungs on imaging." | ( Arrossi, AV; Kirsch, J; Neumann, DR; Wu, G; Yoon, JK, 2006) |
| "We suspected drug-induced pneumonitis, because her history of fever seemed to be related to drug administration for sinusitis." | ( Arakaki, N; Shimoji, T; Tamaki, K; Tohyama, M, 2006) |
| "Gemcitabine-induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy." | ( Bremer, M; Karstens, JH; Schwarte, S; Wagner, K, 2007) |
| "Since pneumonitis may recur during low-dose sirolimus treatment, discontinuation of sirolimus appears to be the safest treatment option." | ( Buchner, NJ; Flecken, M; Rump, LC; Schenker, P; Sellin, L; Viebahn, R; Vonend, O; Weiner, SM, 2007) |
| "He was diagnosed as minocycline-induced pneumonitis and recovered rapidly following corticosteroid therapy." | ( Arai, S; Hirano, S; Hojyo, M; Kato, Y; Kobayashi, N; Kudo, K; Shinohara, Y; Sugiyama, H; Yoshizawa, A, 2007) |
| "Bleomycin-related pneumonitis (BIP) has recently emerged as one of the main causes of death in Hodgkin's disease treated with standard chemotherapy ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)." | ( Bomanji, J; Buchler, T; Lee, SM, 2007) |
| "Finally, in a model of pulmonary inflammation induced by the intravenous injection of Sephadex beads, lung neutrophilia was reduced by 63% following the administration of LTB(4) and PAF antagonists, in contrast with the lack of effect of single drug administration." | ( Bélanger, C; Borgeat, P; Elimam, H; Lefebvre, J; Marleau, S, 2008) |
| "This study demonstrates that acute lung inflammation is significantly attenuated by the treatment with AuE." | ( Caminiti, R; Ciampa, A; Cucinotta, G; Cuzzocrea, S; Darra, E; de Prati, AC; Di Paola, R; Esposito, E; Mariotto, S; Mazzon, E; Suzuki, H; Vincenzi, S, 2008) |
| "We describe a case of drug-induced pneumonitis occurring in a patient treated with these two medications." | ( Dehé, C; Gagnadoux, F; Hureaux, J; Person, C; Priou, P; Racineux, JL; Urban, T, 2008) |
| "We report two cases of drug-induced pneumonitis in two patients treated for breast cancer who were diagnosed by FDG-PET examination." | ( Ameshima, S; Demura, Y; Ishizaki, T; Mizuno, S; Morikawa, M; Okazawa, H, 2008) |
| "Based on this case amiodarone-related pneumonitis will be discussed, which due to a lack of pathognomonic symptoms is often difficult to diagnose and for which there are few treatment options available." | ( Fisseler-Eckhoff, A; Ghezel-Ahmadi, V; Kürschner, VC; Obenhaus, T; Schirren, J; Schmitz, JE, 2008) |
| "Awareness of pneumonitis and pleurisy, potentially life-threatening complications of MTX, is very necessary and important to early recognition and treatment." | ( Ding, Z; Qian, J; Wang, Y; Xie, X; Zhang, D, 2008) |
| "This exacerbation of lung inflammation was rescued by intranasal administration of SP-A." | ( Fukuhara, T; Inoue, A; Kanehira, M; Kikuchi, T; Kuroki, Y; Maemondo, M; Nukiwa, T; Saijo, Y; Suzuki, T; Xin, H, 2008) |
| "Drug-induced pneumonitis is a serious and an unpredictable side effect of chemotherapy in patients with malignant lymphoma." | ( Daimaru, O; Fukaya, N; Imai, T; Ito, S; Nagata, T; Uchida, H; Yamane, T; Yoshiya, K, 2008) |
| "Acute pulmonary inflammation was induced by intracheal instillation with LPS, treatment with LF at dosages of 3, 10 and 30 mg/kg significantly reduced the LPS-induced inflammatory cells, including neutrophils, macrophages and lymphocytes accumulation in bronchoalveolar lavage fluids (BALF), among these inflammatory cells, LF predominately inhibited neutrophil infiltration, and the maximal effect (30 mg/kg) was as comparable as dexamethasone treatment at 1 mg/kg." | ( Dong, XW; Wu, XM; Xie, QM; Xie, YC; Yan, XF, 2009) |
| "The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD." | ( Bard, J; Cunningham, K; Goldman, SJ; Hotchandani, R; Li, J; Li, W; Mansour, TS; McFadyen, I; Morgan, P; Schlerman, F; Sypek, J; Tam, S; Williams, C; Wu, J; Wu, Y; Xu, X, 2009) |
| "Mucositis and pneumonitis are the most commonly reported toxicities, but they rarely lead to treatment discontinuation." | ( Giles, F; Kelly, K; Mahalingam, D; Mita, A; Mita, M; Sankhala, K, 2009) |
| "Our data suggest that augmented lung inflammation after fish oil supplementation may be due to the reduction of PGE(2) production in the lung and these dichotomous results bring into question the role of fish oil supplementation in the treatment of asthma." | ( Goleniewska, K; Liu, W; Morrow, JD; Peebles, RS; Porter, NA; Yin, H, 2009) |
| "Few noninvasive biomarkers for pulmonary inflammation are currently available that can assess the lung-specific response to antiinflammatory treatments." | ( Bedient, TJ; Chen, DL; Ferkol, TW; Isakow, W; Kozlowski, J; Mintun, MA; Rosenbluth, DB; Schuster, DP; Thomas, B; Walter, MJ, 2009) |
| "The present study investigates lung inflammation and remodelling in an animal model of chronic gastro-oesophageal reflux disease (GORD), and the effectiveness of pretreatments with tiotropium, atropine and dexamethasone." | ( Advenier, C; Chen, H; Cui, Y; Devillier, P; Kuang, X; Wang, H; Xia, Z; Xu, Z; Zemoura, L; Zhu, L, 2010) |
| "Acute lung inflammation in wild type, ER alpha or ER beta knockout animals was induced by pleural injection of carrageenan; female mice were used and sham operated, ovariectomized, or ovariectomized and treated with 17beta-estradiol (E(2)) before carrageenan." | ( Crisafulli, C; Cuzzocrea, S; Krust, A; Maggi, A; Mazzon, E; Sala, A; Vegeto, E, 2010) |
| "SB216763 prevented lung inflammation and the subsequent fibrosis when coadministered with BLM." | ( Agostini, C; Biasutto, L; Brunetta, E; Cabrelle, A; Calabrese, F; Cinetto, F; Facco, M; Garbisa, S; Gattazzo, C; Gnoato, M; Gurrieri, C; Montini, B; Niero, R; Piazza, F; Semenzato, G, 2010) |
| "In the LPS-induced lung inflammation model, pre-treatment with Man-cationic liposome/50μg NFκB decoy complex significantly inhibited the release of TNF-α, IL-1β and CINC-1, neutrophil infiltration and NFκB activation compared with naked NFκB decoy, cationic liposome/NFκB decoy complex and Man-cationic liposome/scrambled decoy complex treatments." | ( Hashida, M; Higuchi, Y; Kawakami, S; Wijagkanalan, W; Yamashita, F, 2011) |
| "The girl developed sterile pneumonitis during a disease flare-up, and high-dose corticosteroid therapy was quickly initiated." | ( Bessis, D; Girard, C; Guillot, B; Kluger, N, 2011) |
| "Allergic lung inflammation is impaired in diabetic rats and is restored by insulin treatment." | ( Anger, DB; Jancar, S; Martins, DO; Martins, JO; Sannomiya, P; Wittlin, BM, 2010) |
| "PET with [(11)C]3a using a rat model of lung inflammation showed a significant signal in the lipopolysaccharide-treated lung." | ( Fujinaga, M; Fukumura, T; Hatori, A; Kawamura, K; Kumata, K; Nengaki, N; Ogawa, M; Wakizaka, H; Yamasaki, T; Yanamoto, K; Yoshida, Y; Yui, J; Zhang, MR, 2011) |
| "Neither bacterial clearance nor pulmonary inflammation was affected by anticoagulant therapy." | ( Cornet, AD; Groeneveld, AB; Hofstra, JJ; Levi, M; Roelofs, JJ; Schultz, MJ; van den Boogaard, FE; van der Poll, T; Vlaar, AP, 2011) |
| "We attributed the pneumonitis to sirolimus on account of clinical and radiological resolution within 1 to 6 months of stopping treatment." | ( Foulet-Rogé, A; Gagnadoux, F; Goupil, F; Kernaonet, E; Lebas, FX; Molinier, O; Paris, A, 2012) |
| "CT evidence of pneumonitis was seen in 14/46 pts (30%), at a median of 56days on mTOR inhibitor treatment (range 31-214 days)." | ( Cho, DC; Choueiri, TK; Dabydeen, DA; Jagannathan, JP; Krajewski, K; Pedrosa, I; Ramaiya, N; Schutz, FA, 2012) |
| "Weight loss, lung inflammation and lung injury severity were similar in the rosuvastatin and control treated mice." | ( Budinger, GR; Chiarella, SE; Gonzalez, A; Misharin, AV; Mutlu, GM; Perlman, H; Radigan, KA; Soberanes, S; Urich, D; Wunderink, RG, 2012) |
| "Bortezomib-induced pneumonitis was reported to occur relatively soon after the first administration of bortezomib." | ( Itoh, K; Sasaki, M; Yamaguchi, T, 2012) |
| "Progressive pulmonary inflammation and emphysema have been implicated in the progression of chronic obstructive pulmonary disease (COPD), while current pharmacological treatments are not effective." | ( Chen, X; Cui, ZL; Guan, XJ; Guo, XJ; Han, FF; Song, L; Xu, WG, 2013) |
| "Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for ≥1 year but did not result in treatment discontinuations." | ( Anak, O; Bahl, A; Bavbek, S; Bracarda, S; Grünwald, V; Karakiewicz, P; Kim, D; Ou, YC; Panneerselvam, A; Rha, SY; van den Eertwegh, AJ, 2013) |
| "Sevoflurane treatment can attenuate lung inflammation in rats with lipopolysaccharide-induced acute lung injury." | ( Liu, GZ; Song, SY; Tian, JM; Yang, SM; Yue, XQ; Zhou, B, 2013) |
| "This is the first report of RFP-induced pneumonitis occurring during adjunct steroid therapy." | ( Goto, K; Kimura, K; Koma, Y; Koyama, M; Masuya, D; Matsumoto, Y; Matsuoka, H; Nakashima, N; Suzuki, Y; Yoshida, C; Yoshimatsu, H, 2013) |
| "Estradiol treatment is able to reduce lung inflammation due to intestinal I/R, but with the concomitant blockade of NOS activity, this effect is abolished." | ( Assis-Ramos, MM; Breithaupt-Faloppa, AC; Couto, GK; de Assis Ramos, MM; Fantozzi, ET; Lino-dos-Santos-Franco, A; Oliveira-Filho, RM; Rossoni, LV; Tavares-de-Lima, W; Vargaftig, BB; Vitoretti, LB, 2013) |
| "Silica-induced lung inflammation increased the incidence and multiplicity of lung cancer in mice treated with N-nitrosodimethylamine, a carcinogen found in tobacco smoke." | ( Agorreta, J; Ajona, D; Blanco, D; Bleau, AM; de Biurrun, G; Freire, J; Guruceaga, E; Montuenga, LM; Pio, R; Segura, V, 2013) |
| "To reduce the lung inflammation caused by intestinal I/R, we have acutely treated male rats with estradiol." | ( Boris Vargaftig, B; Breithaupt-Faloppa, AC; de Sousa, PT; Lino Dos Santos Franco, A; Oliveira-Filho, RM; Rodrigues, Ada S; Romero, DC; Tavares de Lima, W; Thais Fantozzi, E, 2014) |
| "High-dose IVIG decreased lung inflammation scores and BAL TGF-β1 levels and this therapy would give even better results if it is given earlier." | ( Akcan, AB; Coskun, M; Oygucu, SE; Oygur, N; Ozbilim, G; Ozbudak, IH; Ozel, D, 2014) |
| "After insulin treatment, the lung inflammation in diabetics increased to levels comparable to the non-diabetics." | ( Capelozzi, VL; Filgueiras, LR; Jancar, S; Martins, JO, 2014) |
| "MTX-induced pneumonitis is a rare, although potentially severe complication of this treatment." | ( Fiehn, C, 2015) |
| "Drug-related pneumonitis was noted on CT in 58% of Waldenström macroglobulinemia patients treated with mTOR inhibitor therapy." | ( Boswell, EN; Ghobrial, IM; Hatabu, H; Nishino, M; Ramaiya, NH, 2015) |
| "This study aimed to clarify the risk of pneumonitis in patients with esophageal cancer who receive taxane therapy after chemoradiotherapy." | ( Endo, M; Fukutomi, A; Hamauchi, S; Kishida, Y; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2018) |
| "Neutrophilic pulmonary inflammation was induced in mice by intratracheal administration of lipopolysaccharide." | ( Higashimoto, I; Inoue, H; Kubota, S; Machida, K; Okuno, T; Shirato, M; Watanabe, M; Yokomizo, T, 2015) |
| "Twelve horses underwent acute lung inflammation through exposure to allergens known to cause RAO, after which they received treatment with either tamoxifen or dexamethasone." | ( Folch, H; Galesio, JS; Henriquez, C; Morales, N; Morán, G; Perez, B; Sarmiento, J; Uberti, B, 2016) |
| "To assess lung inflammation, C57BL/6 mice were administered bare or amine-functionalized silica NPs via intra-tracheal instillation." | ( Adamcakova-Dodd, A; Larsen, SC; Lehman, SE; Morris, AS; Salem, AK; Thorne, PS; Wongrakpanich, A, 2016) |
| "Drug-related pneumonitis was noted in 21% of the advanced NET patients treated with everolimus." | ( Brais, LK; Brooks, NV; Hatabu, H; Kulke, MH; Nishino, M; Ramaiya, NH, 2016) |
| "We report on two cases of anti-PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA approval." | ( Awad, MM; Chambers, ES; Chong, CR; Gray, SW; Hatabu, H; Hodi, FS; Jänne, PA; Marcoux, JP; Nishino, M; Ramaiya, NH, 2016) |
| "Two patients died from severe lupus pneumonitis within 2 weeks of admission despite treatment with ventilation, steroids, cyclophosphamide and intravenous immunoglobulin." | ( Jobli, AT; Teh, CL; Wan, SA, 2016) |
| "Bleomycin-induced pneumonitis (BIP) is a well-known and potentially fatal side effect in metastatic testicular cancer patients treated with bleomycin, etoposide, and cisplatin chemotherapy." | ( Altena, R; Bongaerts, AH; de Vries, EG; den Hollander, MW; Gietema, JA; Lubberts, S; Meijer, C; Nuver, J; Oosting, SF; Walenkamp, AM; Westerink, ND; Wolf, RF, 2016) |
| "Lamotrigine can cause pneumonitis, and this side effect should be suspected in patients who are being treated with lamotrigine and presenting with progressive dyspnoea." | ( Davidsen, JR; Madsen, HD, 2016) |
| "Both cases developed interstitial pneumonitis at 8 weeks after administration of anagrelide." | ( Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M, 2017) |
| "The effects of LED treatment on lung inflammation may be modulated by IL-10, IFN-gamma, and by mast cells." | ( Damazo, AS; Dos Santos, A; Evangelista, MIS; Ligeiro-de-Oliveira, AP; Lino-Dos-Santos-Franco, A; Marcos, RL; Pavani, C; Siqueira, VPC, 2017) |
| "When administered to mice, FlgE induced lung inflammation and enhanced the Th2-biased humoral response to ovalbumin." | ( Chen, L; Duan, K; Li, W; Liang, Z; Lin, D; Liu, B; Shen, Y; Song, P; Tang, H; Wang, M; Wang, Y; Yuan, Q; Zhao, G, 2017) |
| "Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus." | ( Amadori, D; Barone, D; Burgio, SL; De Giorgi, U; Gallà, V; Lolli, C; Maugeri, A; Schepisi, G; Vertogen, B, 2017) |
| "We analysed the association of pneumonitis with outcomes in everolimus treated metastatic renal cell carcinoma (mRCC) patients." | ( Bono, P; Donskov, F; Laukka, M; Peltola, K; Penttilä, P; Rautiola, J, 2017) |
| "Severe lung inflammation and fibrosis were observed in BLM-treated mice." | ( Chen, C; Cheng, MQ; Hong, ZP; Wang, YX; Wang, YY; Yin, JB; Zhang, X, 2018) |
| "We present a case of cytomegalovirus pneumonitis and a case of adenovirus hemorrhagic cystitis in two patients with Philadelphia chromosome-positive acute lymphoblastic leukemia on BCR-ABL TKI treatment and review the literature to summarize the infectious complications based on clinical data." | ( Knoll, BM; Seiter, K, 2018) |
| "Chemotherapy-induced pneumonitis may cause severe morbidity and event death." | ( Berglund-Nord, C; Cohn-Cedermark, G; Haugnes, HS; Langberg, CW; Langberg, MK; Tandstad, T, 2018) |
| "In clinical practice, pneumonitis associated with the combination treatment of ramucirumab and paclitaxel was generally mild, but common." | ( Katayanagi, S; Kawachi, S; Koyama, N, 2018) |
| "Severe lung inflammation and alveolar hemorrhage can be life-threatening in systemic lupus erythematosus (SLE) patients if not treated early and aggressively." | ( Björkbacka, H; Contreras, J; Cunningham, K; Fernando, T; Forbess, L; Gabhann, JN; Ishimori, M; Jefferies, CA; Jin, M; Kearns, G; Kong, W; Kornfeld, H; McCarthy, EM; Molloy, ES; Montano, EN; Murphy, CC; Seo, JJ; Smith, S; Venuturupalli, S; Wallace, D; Weisman, MH; Widaa, A; Wu, PW, 2018) |
| "Meanwhile, berberine relieved pulmonary inflammation and reduced necrosis, inflammatory cell infiltration, and pulmonary edema induced by viral infection in mice when compared with vehicle-treated mice." | ( Chen, XY; Fu, YJ; Jiang, ZY; Qin, HQ; Song, BM; Wang, PC; Weng, YS; Wu, S; Yan, YQ; Zhen, X, 2018) |
| "Radiation pneumonitis is a major dose-limiting complication in thoracic radiation therapy (RT) and presents clinically in the first few months after RT." | ( Alavi, A; Goodman, CR; Houshmand, S; Kalbasi, A; Rice, SR; Saboury, B; Salavati, A; Simone, CB; Vujaskovic, Z; Werner, TJ, 2019) |
| "Steroids were used for the treatment of pneumonitis and rapid improvement was observed." | ( Betsuyaku, T; Ogawa, T; Ohgino, K; Omori, N; Sayama, K; Tanaka, K, 2019) |
| "C3H/HeJ (pneumonitis responding) mice received a single dose of 18 Gy, whole thorax irradiation and a subset were treated with DSePA orally (2." | ( Chaudhari, P; Epari, S; Gandhi, KA; Gandhi, VV; Goda, JS; Gota, V; Jain, VK; Joshi, K; Kembhavi, S; Kunwar, A; Mohanty, B; Priyadarsini, KI; Rane, S; Sadanpurwala, A, 2019) |
| "Severe lung inflammation was present 12 weeks after irradiation, although only a mild change was noted at 2 weeks and could be alleviated by administration of glycyrrhizin." | ( Cao, L; Chen, JY; Li, H; Li, M; Xu, C; Xu, FF; Yi, PQ; Zheng, L; Zhu, Q, 2020) |
| "AF treatment significantly inhibited lung inflammation from cold exposure." | ( Cai, J; Du, Y; Huang, Y; Zhao, C; Zhao, Q, 2019) |
| "Development of hypersensitivity pneumonitis has been reported in association with combination chemotherapy consisting of gemcitabine and paclitaxel." | ( Comlek, S, 2020) |
| "Alzheimer's disease may cause lung inflammation and treatment with low dose of T4 improved MDA level and lung inflammation." | ( Bavarsad, K; Boskabady, MH; Hadjzadeh, MA; Mohammadian Roshan, N; Saadat, S, 2020) |
| "However, worsening of pneumonitis can develop in a subset of patients despite treatment with high doses of corticosteroids." | ( Araya, J; Fujita, Y; Hara, H; Hashimoto, M; Kuwano, K; Minagawa, S; Numata, T; Okuda, K; Takekoshi, D; Utsumi, H; Wakui, H; Watanabe, J, 2020) |
| "Acute lung inflammation was induced by intratracheal administration of LPS in ICR mice." | ( Lei, W; Wang, L; Yao, L; Zhang, S, 2021) |
| "instillation was superior in reducing lung inflammation than the other two routes even treated with a lower concentration of P12." | ( Bao, A; Gong, J; Liu, X; Rao, Y; Shen, L; Sun, L; Wang, L; Yang, H; Zhang, H, 2021) |
| "SUL-151 inhibited the increased pulmonary inflammation and mitochondrial dysfunction in this CS-induced inflammation model, which implied that SUL-151 might be a promising candidate for COPD treatment." | ( Braber, S; Folkerts, G; Garssen, J; Kraneveld, AD; Krenning, G; Leusink-Muis, T; Pelgrim, CE; Swart, DH; van Ark, I; van der Graaf, AC; Wang, L, 2021) |
| "After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone." | ( Ishida, E; Koyama, T; Mizuno, M; Tsuji, Y; Uenishi, Y; Ueno, M; Yokoyama, T, 2021) |
| "Checkpoint inhibitor pneumonitis (CIP) is one of the most challenging adverse events, which pose a huge challenge to clinical diagnosis and treatment, and its incidence in the real world is greatly underestimated." | ( Miao, K; Tian, X; Xu, W; Xu, Y; Zhang, L; Zhang, Y, 2021) |
| "When pulmonary inflammation occurs and other causes of pneumonia are excluded, vancomycin therapy should be discontinued." | ( Lee, YM; Lee, YS, 2021) |
| "Brain death-induced lung inflammation in females is modulated by estradiol treatment." | ( Anunciação, LFD; Armstrong-Jr, R; Breithaupt-Faloppa, AC; Correia, CJ; Coutinho E Silva, RDS; Leuvenink, HGD; Moreira, LFP; Ricardo-da-Silva, FY; Vidal-Dos-Santos, M, 2021) |
| "Allergic lung inflammation was induced in sensitized BALB/c mice through intranasal instillations of ovalbumin (OVA), and mice were pretreated with the PAR2 antagonist ENMD1068 or with the PAR2-activating peptide (PAR2-AP) 1 hour before each OVA challenge." | ( Alves-Filho, JC; DA Silva, JF; Klein, A; Lemos, VNS; Matos, NLA; Oliveira Lima, OSC; Pin Eros, AR; Tavares, JC, 2022) |
| "COVID-19 causes pulmonary inflammation, secondary pulmonary fibrosis (PF); however, there are still no effective treatments for PF." | ( Bao, J; Dou, H; Guo, T; Jiang, K; Jiang, X; You, X; Zhang, C; Zhao, X; Zhu, X, 2022) |
| "We have mimicked the lung inflammation by administering intranasal β-glucan in mice model." | ( Agrawal-Rajput, R; Challagundla, N; Dalai, P; Mandaliya, D; Naik, O; Patel, D; Shah, D; Vora, H; Yadav, S, 2022) |
| "Many current treatment options for lung inflammation and thrombosis come with unwanted side effects." | ( Arjun, N; Brenna, JT; Kocherlakota, C; Kothapalli, KSD; Nagaraju, B; Srinath, A, 2022) |
| "Interstitial lung disease (ILD)/pneumonitis is an adverse event associated with T-DXd; in most cases, it is low grade (grade ≤ 2) and can be treated effectively but may develop to be fatal in some instances." | ( Andre, F; Bartholmai, BJ; Conte, P; Kato, T; Lancaster, LH; Li, BT; Naidoo, J; Nicholson, AG; Nishino, M; Powell, CA; Schumacher-Wulf, E; Shitara, K; Swain, SM; Tsurutani, J, 2022) |
| "Drug-related pneumonitis (DRP) is a potentially lethal complication of osimertinib treatment, but reliable real-world data currently are lacking." | ( Arai, D; Fujimoto, D; Hara, S; Hashimoto, K; Hino, A; Ikeda, H; Inaba, M; Kobe, H; Maruyama, H; Matsumoto, H; Morimoto, T; Oya, Y; Sakata, S; Sakata, Y; Sato, Y; Shibaki, R; Sumikawa, H; Suzuki, H; Tamiya, M; Tsukita, Y; Tsumura, S; Yokoi, T, 2022) |
| "Development of lung inflammation after 6 weeks of HDM administration was confirmed by histology, bronchoalveolar lavage (BAL) cell count and lung cytokine measurements." | ( Emala, C; Kanaya, A; Mikami, M; Yang, M, 2022) |
| "Several case reports of pneumonitis have been associated with immunomodulatory drug therapy, and while most of these exhibit diffuse ground-glass opacities radiographically, our patient presented with a 9 cm lung mass." | ( Finch, K; Sharma, D; Wagner, S, 2023) |
| "Immune-related pneumonitis is an uncommon but potentially life-threatening adverse event associated with anti-programmed cell death protein-1 therapy, and has a higher recurrence rate than that of other pneumonitis." | ( Gao, Q; Li, T; Ma, B; Zhao, L; Zhou, Y, 2023) |
| "However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and tepotinib." | ( Chang, JW; Tseng, LW; Wu, CE, 2022) |
| "Scoring of lung inflammation was performed to observe pathological changes in response to SBP treatment compared to OVA/Alum." | ( Han, BK; Huang, WY; Jeong, I; Kim, JK; Kim, MJ; Kim, YJ; Lee, SH; Oh, SJ; Pan, JH; Shin, EC; Yoon, H, 2022) |
| "Patients with ICI-pneumonitis treated by steroids received IS in 10% of cases." | ( Ammari, S; Besse, B; Camard, M; Cariou, PL; Lambotte, O; Laparra, A; Massayke, S; Michot, JM; Noel, N; Pavec, JL, 2022) |
| "Therefore, we created a PM-induced lung inflammation mice model and demonstrated the effect of probiotic, postbiotic, and their combination treatment on attenuation of PM2." | ( Chiu, HP; Chiu, YH; Lin, MY, 2023) |
| "Therefore, we created a PM-induced lung inflammation mice model and demonstrated the effect of probiotic, postbiotic, and their combination treatment on attenuation of PM2." | ( Chiu, HP; Chiu, YH; Lin, MY, 2023) |
| "Checkpoint inhibitor pneumonitis (CIP) is a relatively rare adverse event and a potential cause of death in patients treated with immune checkpoint inhibitors (ICIs)." | ( Chang, Y; Feng, T; Kai, J; Liang, X; Liu, W; Pu, J; Wang, X; Wu, C, 2022) |
| "Checkpoint inhibitor pneumonitis (CIP) is a relatively rare adverse event and a potential cause of death in patients treated with immune checkpoint inhibitors (ICIs)." | ( Chang, Y; Feng, T; Kai, J; Liang, X; Liu, W; Pu, J; Wang, X; Wu, C, 2022) |
| "Based on the diagnosis of drug-induced pneumonitis due to abemaciclib, the discontinuation of abemaciclib and administration of prednisolone were effective." | ( Kawasaki, T; Kumagai, J; Miyazaki, Y; Okayasu, K, 2023) |
| "Salidroside treatment ameliorated the pulmonary inflammation and M1 polarization of AMs induced by CS, and the process might be mediated by the deactivation of JNK/c-Jun." | ( Feng, H; Kang, J; Yin, Y; Zhang, D; Zheng, R, 2023) |
| "The primary endpoint was a pneumonitis control rate at 6 weeks from the start of the study treatment, defined as complete disappearance or partial improvement of irP in high-resolution CT of the chest." | ( Asada, K; Enomoto, N; Fujii, M; Fujisawa, T; Funayama, S; Furuhashi, K; Goshima, S; Hashimoto, D; Hozumi, H; Ichikawa, S; Ikeda, M; Inami, N; Inoue, Y; Inui, N; Kaida, Y; Karayama, M; Matsuda, H; Matsui, T; Matsuura, S; Suda, T; Suzuki, Y; Toyoshima, M; Uto, T; Yasui, H, 2023) |